SHARE

Waldencast expands into US dermal filler market with Novaestiq acquisition 

Waldencast has acquired Novaestiq Corp. and the US rights to Saypha injectable gels. The move broadens Obagi Medical’s portfolio beyond skincare, targeting the US dermal filler market projected to reach $2bn by 2029.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.